From EHA 2023 to EHA 2024 in clinical perspective
Dr. Dima El-Sharkawi provides an update of the qualitative study looking at patients with CLL who are on their second-line therapyshe presented at EHA 2023. She also looks forward to many interesting talks at EHA 2024, including the continued rise of bispecific antibodies. She also mentions how there are many more choices and different ways of treating diffuse large B cell lymphoma in practice in the UK.
